2,2-dimethylbutyrate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,2-dimethylbutyrate
• 英文别名: 2,2-Dimethylbutanoate
• 化学式: C₆H₁₁O₂
• 分子量: 115.152
• InChiKey: VUAXHMVRKOTJKP-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  40.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2-dimethylbutyrate 、 [2-(1-{[(1s,2r)-2-(Benzoylamino)cyclohexyl]carbonyl}-2,3-dihydro-1h-pyrrolo[3,2-c]quinolin-4-yl)-1h-imidazol-1-yl]methyl pivalate 在 [2-(3aR*,4R*,9bR*)-1-{[(1S,2R)-2-(benzoylamino)cyclohexyl]carbonyl}-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,2-c]quinolin-4-yl)-1H-imidazol-1-yl 、 pivaloyloxymethyl 作用下， 生成 n-((1r,2s)-2-{[4-(1h-Imidazol-2-yl)-2,3-dihydro-1h-pyrrolo[3,2-c]quinolin-1-yl]carbonyl}cyclohexyl)benzamide
  参考文献：
  名称：

  FUSED QUINOLINE DERIVATIVE AND USE THEREOF

  摘要：

  本发明旨在提供具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，并涉及由式（I）表示的化合物，其中R1是氢原子等；R2是氢原子、烃基（可选取取代基等）等；R3是未取代（即不存在）、氢原子等；R4和R5相同或不同，且每个都是氢原子、烃基（可选取取代基等）等；R6是（环状基团可选取取代基等）-羰基等；R7、R8、R9和R10相同或不同，且每个都是氢原子、卤素等；或R7和R8、R8和R9、以及R9和R10可以与相邻的碳原子一起形成环；n是1到5的整数；表示未取代（即不存在）或单键；和表示单键或双键，或其盐等。

  公开号：

  US20090258893A1
• 作为产物：
  描述：

  (2S,4R)-N-(4-chloro-phenyl)-N-[1-(6-methoxy-pyridine-3-carbonyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-acetamide 、 、 碘代三甲硅烷 、 N-(4-chlorophenyl)-N-{(2S,4R)-1-[(6-hydroxypyridin-3-yl)carbonyl]-2-methyl-1,2,3,4-tetrahydroquinolin-4-yl}acetamide 、 methyl 4-bromo-2,2-dimethylbutanoate 、 铝 在 silver carbonate Methyl 4-[(5-1[(2S,4R)-4-[acetyl(4-chlorophenyl)amino]-2-methyl-3,4-dihydroquinolin-1(2H)-yl]carbonyl}pyridin-2-yl)oxy 、 甲醇 、 乙酸乙酯 、 水 、 magnesium sulfate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 以Two products were obtained the O- and N-alkylated product, methyl 4-[(5-{[(2S,4R)-4-[acetyl(4-chlorophenyl)amino]-2-methyl-3,4-dihydroquinolin-1(2H)-yl]carbonyl}pyridin-2-yl)oxy]-2,2-dimethylbutanoate (0.025 g, 32%) and methyl 4-[5-{[(2S,4R)-4-[acetyl(4-chlorophenyl)amino]-2-methyl-3,4-dihydroquinolin-1(2H)-yl]carbonyl}-2-oxopyridin-1(2H)-yl]-2,2-dimethylbutanoate (0.025 g, 32%)的产率得到methyl 4-[(5-{[(2S,4R)-4-[acetyl(4-chlorophenyl)amino]-2-methyl-3,4-dihydroquinolin-1(2H)-yl]carbonyl}pyridin-2-yl)oxy]-2,2-dimethylbutanoate
  参考文献：
  名称：

  PGD2 receptor antagonists for the treatment of inflammatory diseases

  摘要：

  本文揭示的是由结构式(I)和(I-A)所代表的化合物。还揭示了使用这些化合物来抑制G蛋白偶联受体，称为Th2表达的趋化因子受体同源分子或简称“CRTH2”，用于治疗炎症性疾病。结构式(I)和(I-A)中的变量在此定义。

  公开号：

  US20050256158A1

文献信息

• Expanding the Substrate Scope of Acyltransferase LovD9 for the Biosynthesis of Statin Analogues
  作者：Guillermo García‐Marquina、Reyes Núñez‐Franco、Daniel Grajales‐Hernández、Gonzalo Jiménez‐Osés、Fernando López‐Gallego

  DOI：10.1002/chem.202300911

  日期：2023.7.26

  This study identifies new acyl donors for manufacturing statin analogues through the acylation of monacolin J acid by the laboratory evolved acyltransferase LovD9. Vinyl and p‐nitrophenyl esters have emerged as alternate substrates for LovD9‐catalyzed acylation. While vinyl esters can reach product yields as high as the ones obtained by α‐dimethyl butyryl‐S‐methyl‐3‐mercaptopropionate (DMB‐SMMP), the thioester for which LovD9 was evolved, p‐nitrophenyl esters display a reactivity even higher than DMB‐SMMP for the first acylation step yet the acylation product yield is lower. The reaction mechanisms were elucidated through quantum mechanics (QM) calculations.

  摘要 本研究通过实验室进化的酰基转移酶 LovD9 对单加林 J 酸的酰化作用，确定了制造他汀类似物的新酰基供体。乙烯基酯和对硝基苯酯已成为 LovD9 催化酰化反应的替代底物。乙烯基酯的产物产率可与α-二甲基丁酰基-S-甲基-3-巯基丙酸酯（DMB-SMMP）（LovD9催化的硫酯）的产物产率一样高，而对硝基苯酯在第一个酰化步骤中的反应活性甚至高于DMB-SMMP，但酰化产物产率却较低。通过量子力学（QM）计算阐明了反应机理。
• PGD2 receptor antagonists for the treatment of inflammatory diseases
  申请人：Ghosh Shomir

  公开号：US20050256158A1

  公开（公告）日：2005-11-17

  Disclosed herein are compounds represented by Structural Formula (I) and (I-A): Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply “CRTH2” for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

  本文揭示的是由结构式(I)和(I-A)所代表的化合物。还揭示了使用这些化合物来抑制G蛋白偶联受体，称为Th2表达的趋化因子受体同源分子或简称“CRTH2”，用于治疗炎症性疾病。结构式(I)和(I-A)中的变量在此定义。
• FUSED QUINOLINE DERIVATIVE AND USE THEREOF
  申请人：Kajino Masahiro

  公开号：US20090258893A1

  公开（公告）日：2009-10-15

  The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein R 1 is a hydrogen atom and the like; R 2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R 3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R 4 and R 5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R 6 is (cyclic group optionally having substituent(s))-carbonyl, and the like; R 7 , R 8 , R 9 and R 10 are the same or different and each is a hydrogen atom, halogen and the like; or R 7 and R 8 , R 8 and R 9 , and R 9 and R 10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; represents unsubstituted (i.e., absence) or a single bond; and represents a single bond or a double bond, or a salt thereof, and the like.

  本发明旨在提供具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，并涉及由式（I）表示的化合物，其中R1是氢原子等；R2是氢原子、烃基（可选取取代基等）等；R3是未取代（即不存在）、氢原子等；R4和R5相同或不同，且每个都是氢原子、烃基（可选取取代基等）等；R6是（环状基团可选取取代基等）-羰基等；R7、R8、R9和R10相同或不同，且每个都是氢原子、卤素等；或R7和R8、R8和R9、以及R9和R10可以与相邻的碳原子一起形成环；n是1到5的整数；表示未取代（即不存在）或单键；和表示单键或双键，或其盐等。